Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Singh, Seema ^a   Verma, Rakesh ^a   Pradeep, Anamika ^a   Leu, Karen ^b   Mortensen, R Bruce ^b   Young, Peter R ^b   Oyasu, Miho ^b   Schatz, Peter J ^b   Green, Jennifer M ^b   Wojchowski, Don M ^a  

^a Maine Medical Center Research Institute   (United States)

^b AFFYMAX RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GLYCOPEPTIDASE; LIGAND;

ALLELE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL GROWTH; CELL MIGRATION; CELLULAR DISTRIBUTION; CODON USAGE; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; EXON; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; HUMAN; HUMAN CELL; INTERNALIZATION; LIGAND BINDING; MOLECULAR WEIGHT; MUTANT; NONHUMAN; POLYCYTHEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; RABBIT; WILD TYPE; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; ENDOCYTOSIS; GENETICS; INTRACELLULAR SPACE; METABOLISM; MOLECULAR GENETICS; MUTATION; PATHOLOGY; PHENOTYPE; PROTEIN TRANSPORT;

ORYCTOLAGUS CUNICULUS;

ALLELES; AMINO ACID SEQUENCE; BREFELDIN A; CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; ENDOCYTOSIS; ERYTHROID PRECURSOR CELLS; ERYTHROPOIETIN; HUMANS; INTRACELLULAR SPACE; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; MUTATION; PHENOTYPE; POLYCYTHEMIA; PROTEIN TRANSPORT; RECEPTORS, ERYTHROPOIETIN;

EID: 84855772844     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029064     Document Type: Article

References (49)

1. Metcalf D, (2008) Hematopoietic cytokines. Blood 111: 485-491.
2. Perugini M, Varelias A, Sadlon T, D'Andrea RJ, (2009) Hematopoietic growth factor mimetics: from concept to clinic. Cytokine Growth Factor Rev 20: 87-94.
3. Baker SJ, Rane SG, Reddy EP, (2007) Hematopoietic cytokine receptor signaling. Oncogene 26: 6724-6737.
4. Pedersen M, Ronnstrand L, Sun J, (2009) The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. Cell Signal 21: 413-418.
5. Chen J, Olsen J, Ford S, Mirza S, Walker A, et al. (2009) A new isoform of interleukin-3 receptor {alpha} with novel differentiation activity and high affinity binding mode. J Biol Chem 284: 5763-5773.
6. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T, (2011) The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J Biol Chem 286: 1786-1794.
7. Sasson SC, Smith S, Seddiki N, Zaunders JJ, Bryant A, et al. (2010) IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine 50: 58-68.
8. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, et al. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5: 31-42.
9. Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, et al. (2009) AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 23: 1598-1604.
10. Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, et al. (2010) Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 95: 65-70.
11. Germeshausen M, Skokowa J, Ballmaier M, Zeidler C, Welte K, (2008) G-CSF receptor mutations in patients with congenital neutropenia. Curr Opin Hematol 15: 332-337.
12. Liu F, Kunter G, Krem MM, Eades WC, Cain JA, et al. (2008) Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5. J Clin Invest 118: 946-955.
13. Arcasoy MO, Karayal AF, (2005) Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain. Biochim Biophys Acta 1740: 17-28.
14. Perrotta S, Cucciolla V, Ferraro M, Ronzoni L, Tramontano A, et al. (2010) EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One 5: e12015.
15. Huang LJ, Shen YM, Bulut GB, (2010) Advances in understanding the pathogenesis of primary familial and congenital polycythaemia. Br J Haematol 148: 844-852.
16. Jegalian AG, Wu H, (2002) Differential roles of SOCS family members in EpoR signal transduction. J Interferon Cytokine Res 22: 853-860.
17. Sarna MK, Ingley E, Busfield SJ, Cull VS, Lepere W, et al. (2003) Differential regulation of SOCS genes in normal and transformed erythroid cells. Oncogene 22: 3221-3230.
18. Becker V, Schilling M, Bachmann J, Baumann U, Raue A, et al. (2010) Covering a broad dynamic range: information processing at the erythropoietin receptor. Science 328: 1404-1408.
19. Sulahian R, Cleaver O, Huang LJ, (2009) Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia. Blood 113: 5287-5297.
20. Meyer L, Deau B, Forejtnikova H, Dumenil D, Margottin-Goguet F, et al. (2007) beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood 109: 5215-5222.
21. Bulut GB, Sulahian R, Ma Y, Chi NW, Huang LJ, (2011) Ubiquitination regulates the internalization, endolysosomal sorting, and signaling of the erythropoietin receptor. J Biol Chem 286: 6449-6457.
22. Lei JT, Martinez-Moczygemba M, (2008) Separate endocytic pathways regulate IL-5 receptor internalization and signaling. J Leukoc Biol 84: 499-509.
23. Henriques CM, Rino J, Nibbs RJ, Graham GJ, Barata JT, (2010) IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells. Blood 115: 3269-3277.
24. Neumann D, Wikstrom L, Watowich SS, Lodish HF, (1993) Intermediates in degradation of the erythropoietin receptor accumulate and are degraded in lysosomes. J Biol Chem 268: 13639-13649.
25. Komatsu N, Yamamoto M, Fujita H, Miwa A, Hatake K, et al. (1993) Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood 82: 456-464.
26. Sathyanarayana P, Dev A, Fang J, Houde E, Bogacheva O, et al. (2008) EPO receptor circuits for primary erythroblast survival. Blood 111: 5390-5399.
27. Dev A, Fang J, Sathyanarayana P, Pradeep A, Emerson C, et al. (2010) During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable (pro)erythroblast pool. Blood.
28. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T, (1991) Erythropoietin receptor characteristics on primary human erythroid cells. Blood 77: 2583-2590.
29. Elliott S, Busse L, McCaffery I, Rossi J, Sinclair A, et al. (2010) Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods 352: 126-139.
30. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, et al. (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107: 1892-1895.
31. Chun J, Shapovalova Z, Dejgaard SY, Presley JF, Melancon P, (2008) Characterization of class I and II ADP-ribosylation factors (Arfs) in live cells: GDP-bound class II Arfs associate with the ER-Golgi intermediate compartment independently of GBF1. Mol Biol Cell 19: 3488-3500.
32. Usenko T, Eskinazi D, Correa PN, Amato D, Ben-David Y, et al. (2007) Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells. Leuk Lymphoma 48: 134-146.
33. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, et al. (2007) The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109: 4924-4929.
34. Wickrema A, Chen F, Namin F, Yi T, Ahmad S, et al. (1999) Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol 27: 1124-1132.
35. Wojchowski DM, Sathyanarayana P, Dev A, (2010) Erythropoietin receptor response circuits. Curr Opin Hematol 17: 169-176.
36. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, et al. (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227-236.
37. Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, et al. (2003) Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 12: 1239-1250.
38. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, et al. (2000) CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275: 29338-29347.
39. Liu L, Damen JE, Ware M, Hughes M, Krystal G, (1997) SHIP, a new player in cytokine-induced signalling. Leukemia 11: 181-184.
40. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, et al. (2009) A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 361: 1848-1855.
41. Carraway MS, Suliman HB, Jones WS, Chen CW, Babiker A, et al. (2010) Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart. Circ Res 106: 1722-1730.
42. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, et al. (2008) Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A 105: 6998-7003.
43. Choi D, Schroer SA, Lu SY, Wang L, Wu X, et al. (2010) Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 207: 2831-2842.
44. Tong W, Zhang J, Lodish HF, (2005) Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 105: 4604-4612.
45. Forejtnikova H, Vieillevoye M, Zermati Y, Lambert M, Pellegrino RM, et al. (2010) Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood 116: 5357-5367.
46. Yoshimura A, D'Andrea AD, Lodish HF, (1990) Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. Proc Natl Acad Sci U S A 87: 4139-4143.
47. He TC, Zhuang H, Jiang N, Waterfield MD, Wojchowski DM, (1993) Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with an essential erythropoietin receptor subdomain. Blood 82: 3530-3538.
48. Patnaik MM, Tefferi A, (2009) The complete evaluation of erythrocytosis: congenital and acquired. Leukemia 23: 834-844.
49. Motohashi T, Nakamura Y, Osawa M, Hiroyama T, Iwama A, et al. (2001) Increased cell surface expression of C-terminal truncated erythropoietin receptors in polycythemia. Eur J Haematol 67: 88-93.